ES2532948T3 - Composición tópica para el tratamiento de queratosis actínica - Google Patents

Composición tópica para el tratamiento de queratosis actínica Download PDF

Info

Publication number
ES2532948T3
ES2532948T3 ES09776876.6T ES09776876T ES2532948T3 ES 2532948 T3 ES2532948 T3 ES 2532948T3 ES 09776876 T ES09776876 T ES 09776876T ES 2532948 T3 ES2532948 T3 ES 2532948T3
Authority
ES
Spain
Prior art keywords
treatment
actinic keratosis
topical composition
alcohols
mixtures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09776876.6T
Other languages
English (en)
Inventor
Manfred Melzer
Carmen Matthies
Klaus Treudler
Christoph Willers
Henning Mallwitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almirall Hermal GmbH
Original Assignee
Almirall Hermal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40039993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2532948(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Hermal GmbH filed Critical Almirall Hermal GmbH
Application granted granted Critical
Publication of ES2532948T3 publication Critical patent/ES2532948T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composición tópica en gel que comprende (a) del 0,25 al 4,5 % en peso de agente activo para el tratamiento de queratosis actínica seleccionado del grupo que consiste en inhibidores de ciclooxigenasa, inmunomoduladores tópicos, antimetabolitos y mezclas de los mismos, (b) un agente queratolíticamente activo, (c) un formador de gel y (d) un disolvente orgánico seleccionado del grupo que consiste en alcoholes C1-C10, ésteres de alcoholes C1-C10 con ácidos carboxílicos C1-C10, cetonas de alquilo C3-C8 y mezclas de los mismos y que comprende menos del 5 % en peso de agua para su uso en el tratamiento de queratosis actínica.

Description

imagen1
imagen2
imagen3
imagen4
imagen5

Claims (1)

  1. imagen1
    imagen2
ES09776876.6T 2008-07-07 2009-06-29 Composición tópica para el tratamiento de queratosis actínica Active ES2532948T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08012237 2008-07-07
EP08012237A EP2143421A1 (en) 2008-07-07 2008-07-07 Topical composition for the treatment of actinic keratosis
PCT/EP2009/004682 WO2010003568A1 (en) 2008-07-07 2009-06-29 Topical composition for the treatment of actinic keratosis

Publications (1)

Publication Number Publication Date
ES2532948T3 true ES2532948T3 (es) 2015-04-06

Family

ID=40039993

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09776876.6T Active ES2532948T3 (es) 2008-07-07 2009-06-29 Composición tópica para el tratamiento de queratosis actínica

Country Status (31)

Country Link
US (1) US8569320B2 (es)
EP (2) EP2143421A1 (es)
JP (2) JP5654987B2 (es)
KR (1) KR101689898B1 (es)
CN (2) CN104825384A (es)
AR (1) AR072685A1 (es)
AU (1) AU2009267471B2 (es)
BR (1) BRPI0915439B8 (es)
CA (1) CA2729974A1 (es)
CL (1) CL2010001642A1 (es)
CO (1) CO6351710A2 (es)
CY (1) CY1116111T1 (es)
DK (1) DK2315581T3 (es)
EA (1) EA019533B1 (es)
EC (1) ECSP11010762A (es)
ES (1) ES2532948T3 (es)
HR (1) HRP20150222T1 (es)
IL (1) IL210134A (es)
ME (1) ME02147B (es)
MX (1) MX2011000054A (es)
MY (1) MY158428A (es)
NZ (1) NZ590288A (es)
PE (1) PE20110330A1 (es)
PL (1) PL2315581T3 (es)
PT (1) PT2315581E (es)
RS (1) RS53887B1 (es)
SI (1) SI2315581T1 (es)
TW (1) TWI433692B (es)
UA (1) UA101044C2 (es)
WO (1) WO2010003568A1 (es)
ZA (1) ZA201100653B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011044008A1 (en) * 2009-10-08 2011-04-14 Schering-Plough Healthcare Products, Inc. Low ether composition and delivery apparatus
JP5950528B2 (ja) * 2011-09-30 2016-07-13 小林製薬株式会社 皮膜形成性外用製剤
WO2013088380A1 (en) * 2011-12-12 2013-06-20 Leo Laboratories Limited Gel compositions
NZ606177A (en) * 2012-01-30 2014-03-28 Dolorgiet Gmbh & Co Kg Compositions for the treatment of actinic keratosis
GB201222405D0 (en) * 2012-12-12 2013-01-23 Leo Lab Ltd Gel compositions
MA40447A (fr) 2014-07-31 2016-02-04 Sun Pharmaceutical Ind Ltd Composition pharmaceutique orale d'isotrétinoïne
MX385843B (es) 2014-09-12 2025-03-18 Antibiotx Aps Uso antibacteriano de salicilanilidas halogenadas.
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
WO2017008831A1 (en) * 2015-07-10 2017-01-19 Infectopharm Arzneimittel Und Consilium Gmbh Use of potassium hydroxide in the treatment of actinic keratosis
GB201604484D0 (en) 2016-03-16 2016-04-27 Antibiotx Aps And Københavns Uni University Of Copenhagen Topical antibacterial compositions
WO2018165647A1 (en) 2017-03-10 2018-09-13 Athenex, Inc. Methods of treating and/or preventing actinic keratosis
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
US12129265B2 (en) 2020-07-21 2024-10-29 Ankh Life Sciences Limited Therapeutic agents and uses thereof
US20220175769A1 (en) * 2020-12-08 2022-06-09 Ankh Life Sciences Limited Method of treatment of actinic keratoses
DK202370132A1 (en) * 2023-03-14 2024-10-10 Repoceuticals Aps Compositions for use in the treatment of actinic keratosis

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2802005A (en) 1957-08-06 S-eluorourace
US4234599A (en) * 1978-10-04 1980-11-18 Scott Eugene J Van Treatment of skin keratoses with α-hydroxy acids and related compounds
US5091171B2 (en) * 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
US5167649A (en) * 1988-08-22 1992-12-01 Zook Gerald P Drug delivery system for the removal of dermal lesions
US5093360A (en) * 1989-04-07 1992-03-03 Yu Ruey J Retinal, derivatives and their therapeutic use
GB9023701D0 (en) * 1990-10-31 1990-12-12 Efamol Holdings Medical treatment
JP3117502B2 (ja) * 1991-08-27 2000-12-18 株式会社資生堂 皮膚外用剤
US5627187A (en) 1995-04-12 1997-05-06 Katz; Bruce E. 5-FU for treating actinic kerotoses
HU0200901D0 (es) * 1996-06-20 2002-08-28 Lavipharm Sa
US5993787A (en) * 1996-09-13 1999-11-30 Johnson & Johnson Consumer Products, Inc. Composition base for topical therapeutic and cosmetic preparations
US5955097A (en) * 1996-10-18 1999-09-21 Virotex Corporation Pharmaceutical preparation applicable to mucosal surfaces and body tissues
US6462071B1 (en) * 2000-03-02 2002-10-08 Vitreo-Retinal Technologies, Inc. Agents for intravitreal administration to treat or prevent disorders of the eye
ES2223277B1 (es) * 2003-06-19 2006-03-01 Fernando Bouffard Fita Composicion anestesica para administracion topica.
CN1856294A (zh) * 2003-08-25 2006-11-01 弗米克斯有限公司 渗透性药物泡沫
US20050137164A1 (en) * 2003-09-22 2005-06-23 Moshe Arkin Diclofenac compositions for the treatment of skin disorders
CA2570599C (en) * 2004-06-24 2012-03-27 Idexx Laboratories, Inc. Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same
US20070053984A1 (en) 2005-03-03 2007-03-08 Monique Spann-Wade Topical gels compositions
EP1890687B1 (en) * 2005-06-14 2008-09-17 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Stable pharmaceutical gel of diclofenac sodium
US7851431B2 (en) * 2005-07-27 2010-12-14 Prescription Dispensing Laboratories Treatment of actinic keratoses with calcium channel blockers
US20070264317A1 (en) * 2006-05-15 2007-11-15 Perrigo Israel Pharmaceuticals Ltd. Imiquimod cream formulation
WO2008047857A1 (fr) * 2006-10-18 2008-04-24 Fujifilm Corporation Procédé de production d'une composition comprenant un composé difficilement soluble dans l'eau incorporé dans une matrice hydrophile et préparation pour une utilisation externe comprenant un agent ou médicament anticancéreux ayant un coefficient de partage octanol/eau (log p) de -3,0 ou plus mais pas plus de 3,0, incorporé

Also Published As

Publication number Publication date
TWI433692B (zh) 2014-04-11
EP2315581B1 (en) 2014-12-17
HK1154793A1 (en) 2012-05-04
US8569320B2 (en) 2013-10-29
AU2009267471A1 (en) 2010-01-14
BRPI0915439B1 (pt) 2019-10-08
EP2315581A1 (en) 2011-05-04
PE20110330A1 (es) 2011-06-11
JP2011526934A (ja) 2011-10-20
NZ590288A (en) 2012-08-31
CN102088957A (zh) 2011-06-08
WO2010003568A1 (en) 2010-01-14
EA201100020A1 (ru) 2011-06-30
CO6351710A2 (es) 2011-12-20
ECSP11010762A (es) 2012-03-30
US20110301130A1 (en) 2011-12-08
ZA201100653B (en) 2011-10-26
BRPI0915439A2 (pt) 2015-11-10
MX2011000054A (es) 2011-11-04
KR101689898B1 (ko) 2016-12-26
RS53887B1 (sr) 2015-08-31
AU2009267471B2 (en) 2014-06-05
CA2729974A1 (en) 2010-01-14
SI2315581T1 (sl) 2015-05-29
HRP20150222T1 (hr) 2015-05-22
IL210134A (en) 2015-06-30
CL2010001642A1 (es) 2011-04-08
PT2315581E (pt) 2015-04-02
TW201006507A (en) 2010-02-16
EP2143421A1 (en) 2010-01-13
EA019533B1 (ru) 2014-04-30
ME02147B (me) 2015-10-20
WO2010003568A8 (en) 2011-02-03
JP2015038129A (ja) 2015-02-26
BRPI0915439B8 (pt) 2021-05-25
AR072685A1 (es) 2010-09-15
IL210134A0 (en) 2011-02-28
KR20110027838A (ko) 2011-03-16
MY158428A (en) 2016-10-14
DK2315581T3 (en) 2015-03-23
PL2315581T3 (pl) 2015-06-30
CN104825384A (zh) 2015-08-12
CY1116111T1 (el) 2017-02-08
JP5654987B2 (ja) 2015-01-14
UA101044C2 (ru) 2013-02-25

Similar Documents

Publication Publication Date Title
ES2532948T3 (es) Composición tópica para el tratamiento de queratosis actínica
ES2575565T3 (es) Procedimiento para la preparación de monohidrato de treprostinilo y su utilización para el almacenamiento y el envío
ES2502472T3 (es) Composición adhesiva para su uso en un inmunosensor
ES2575994T3 (es) Sistema y procedimiento para preparar, aplicar y retirar un revestimiento superior para gráficos despegables
ES2536206T3 (es) Parche medicinal
ES2500068T3 (es) Inhibidores heterocíclicos de MEK y métodos de uso de los mismos
ES2496092T3 (es) El uso de amisulprida para tratar náuseas y vómitos posoperatorios
ES2661582T3 (es) Efecto antiinflamatorio de la celulosa microfibrilada
ES2543957T3 (es) Nueva composición farmacéutica para el tratamiento de infecciones fúngicas
CL2013003163A1 (es) Composición transdermica de ibuprofeno, util en el tratamiento del dolor o la inflamacion.
PE20121359A1 (es) Composicion farmaceutica que comprende oligopeptidos
EA201490178A1 (ru) Стабилизированные композиции для местного применения, содержащие микрокапсулы с ядром и оболочкой
ES2646037T3 (es) Composiciones de acabado, sustratos recubiertos y métodos relacionados
NI201000179A (es) Pirimidin-5-carboxamidas sustituidas 281
PE20190914A1 (es) Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico
AR073904A1 (es) Formas cristalinas de derivados de tiazolidinona utiles como inmunomoduladores
ES2546198T3 (es) Tratamiento contra la glomerulonefritis
CO6290654A2 (es) Derivados de salinosporamida como inhibidores de proteasoma
AR097931A1 (es) Derivados de diazacarbazol como ligandos de tau para pet
ES2487496T3 (es) Agente para aliviar el síndrome metabólico
ES2517491T3 (es) Estabilizador de los vasos linfáticos
ES2660019T3 (es) Parche que contiene diclofenaco y tiocolchicósido
ES2564521T3 (es) Métodos y composiciones para mejorar la entrada de aire en mezclas de cemento
AR081017A1 (es) Composicion topica y uso de la misma para la profilaxis y el tratamiento de los defectos relacionados con dermopatias inflamatorias
WO2013103925A3 (en) Liposomally encapsulated reduced glutathione for management of cancer with other uses and methods